Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, particularly in oncology, cardiovascular, renal, and respiratory diseases. Its competitive position is bolstered by a robust pipeline of innovative therapies and strategic partnerships, particularly in the U.S. and Europe.
AstraZeneca generates revenue primarily through the sale of patented pharmaceuticals, leveraging its strong R&D capabilities to bring innovative drugs to market. The company benefits from pricing power due to its differentiated product offerings and a strong brand presence in key therapeutic areas.
FDA approval of new drugs or indications, particularly in oncology
Sales performance of key products like Tagrisso and Farxiga
M&A activity or strategic partnerships that enhance the pipeline
Regulatory changes impacting drug pricing or reimbursement
Regulatory changes that could impact drug pricing or approval processes
Technological disruption in drug development or delivery methods
Increased competition from generic drugs as patents expire
Emerging biotech firms with innovative therapies in key therapeutic areas
Moderate debt levels could limit financial flexibility in downturns
Potential pension obligations impacting cash flow
moderate - AstraZeneca's performance is somewhat linked to GDP growth as healthcare spending tends to increase in stronger economic conditions, but demand for essential medicines remains stable even in downturns.
Interest rates impact AstraZeneca primarily through the cost of capital for R&D investments and potential changes in consumer spending on healthcare. Higher rates could compress valuations as future cash flows are discounted more heavily.
minimal - AstraZeneca operates with a manageable debt-to-equity ratio of 0.72, indicating limited reliance on credit markets.
growth - AstraZeneca's strong pipeline and innovation potential attract growth-focused investors.
moderate - historical volatility reflects the biotech sector's inherent risks, but AstraZeneca's established portfolio provides some stability.
